The Advanced Medical Development (AMD) Program Office of Naval Medical Research Center (NMRC), has announced intentions to award a sole source contract Sanaria, Inc. to support malaria countermeasure efforts.
Sanaria will develop a large scale automated manufacturing process that will produce large amounts of malaria vaccine to be utilized in future Phase 3 clinical trials.
The vaccine must utilize irradiated aseptic, purified, cryopreserved, attenuated, metabolically active Plasmodium falciparum (Pf) sporozoites (SPZ) extracted from mosquitos that are grown and incubated. In addition, the vaccine must be administered intravenously.
Source: FBO.gov
